SCHEMBL21035618

SCHEMBL21035618

O=C(O)[C@@H]1CC(Nc2ccc(Cl)cc2)CN1S(=O)(=O)c1ccc2cc(OC3CCCC3)ccc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ITGB1 P05556 2/20 0.40
ITGA4 P13612 2/20 0.40
HTR1A P08908 2/20 0.39
HTR7 P34969 2/20 0.39
HTR5A P47898 2/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
ADRA1A P35348 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39
HTR4 Q13639 1/20 0.39
MMP9 P14780 3/20 0.39
MMP1 P03956 3/20 0.39
MMP3 P08254 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21035616 0.88 CNR2 (0.40) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035399 0.87 HTR1A (0.44) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035314 0.87 HTR1A (0.44) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035612 0.86 GHSR (0.38) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035615 0.86 GHSR (0.38) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035614 0.86 GHSR (0.38) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035666 0.83 ITGB1 (0.49) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035001 0.80 ITGB1 (0.47) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035412 0.80 ITGB1 (0.47) ITGB1ITGA4HTR1AHTR7HTR5A
SCHEMBL21035523 0.80 AKR1C3 (0.43) CA12CA1CA2CA9ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed